189 related articles for article (PubMed ID: 35615718)
1. Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy-Preliminary Results From a Prospective Single-Center Study.
Sarnat-Kucharczyk M; Świerkot M; Handzlik G; Kulawik G; Jagoda K; Grochoła-Małecka I; Fryżewska J; Mrukwa-Kominek E; Chudek J
Front Endocrinol (Lausanne); 2022; 13():871009. PubMed ID: 35615718
[TBL] [Abstract][Full Text] [Related]
2. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
3. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
4. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
5. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
6. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
7. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and Side Effects of Lateral Orbital Wall Decompression Including the Orbital Rim in Patients with Graves' Orbitopathy].
Horn M; Schittkowski MP
Klin Monbl Augenheilkd; 2019 Jan; 236(1):17-24. PubMed ID: 30690696
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
13. Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience.
Pérez-Moreiras JV; Varela-Agra M; Prada-Sánchez MC; Prada-Ramallal G
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670151
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
[TBL] [Abstract][Full Text] [Related]
15. Double vision is a major manifestation in moderate to severe graves' orbitopathy, but it correlates negatively with inflammatory signs and proptosis.
Laurberg P; Berman DC; Pedersen IB; Andersen S; Carlé A
J Clin Endocrinol Metab; 2015 May; 100(5):2098-105. PubMed ID: 25695893
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
17. Restoration of vision by combined experimental antithymocyte therapy, and orbital radiation with high-dose steroids for severe, acute, steroid-refractory, congestive thyroid orbitopathy.
Sarnat-Kucharczyk M; Pojda-Wilczek D; Świerkot M; Kulawik G; Mrukwa-Kominek E
Doc Ophthalmol; 2024 Feb; 148(1):47-55. PubMed ID: 37775645
[TBL] [Abstract][Full Text] [Related]
18. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]